Video
Author(s):
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
An initiative is looking at the management of these AEs. The idea of the workshop is to help offer guidance and educational initiatives with the intention of improving patient outcomes following immunotherapy—generally with checkpoint inhibitors as they are used most commonly, says Zibelman.
The goal of a workshop being conducted by the Association of Community Cancer Centers Immuno-Oncology Institute is to provide interventions of education both to patients, as well as to staff and faculty, to improve their understanding of the relationship between AEs and patient outcomes. As part of the workshop, 2 cancer centers have been selected to participate with the program. This will offer education to patients and physicians alike, says Zibelman.
Zibelman explains that this will take the form of tumor boards. Members of the committee will monitor the centers to see whether there are improvements in how physicians manage their patients, how they recognize these side effects, and how they treat them. The ultimate goal is to show that these interventions can make a difference and can be used and repurposed for other organizations as well.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber
2 Commerce Drive
Cranbury, NJ 08512